CLINICAL TRIALS PROFILE FOR PERFLUBRON
✉ Email this page to a colleague
All Clinical Trials for perflubron
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02616770 ↗ | Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects. | Completed | SolAeroMed Inc. | Phase 1 | 2014-03-01 | To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy subjects. |
| NCT03041740 ↗ | Fluid Filled Lung Oxygenation Assistance Trial | Active, not recruiting | ADAGP Charitable Foundation dba Auto Dealers CARing for Kids Foundation | Phase 1 | 2017-06-27 | The primary study objective is to assess the safety and feasibility of perfluorooctylbromide (PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia (BPD). |
| NCT03041740 ↗ | Fluid Filled Lung Oxygenation Assistance Trial | Active, not recruiting | Auto Dealers Caring for Kids Foundation | Phase 1 | 2017-06-27 | The primary study objective is to assess the safety and feasibility of perfluorooctylbromide (PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia (BPD). |
| NCT03041740 ↗ | Fluid Filled Lung Oxygenation Assistance Trial | Active, not recruiting | Children's Hospital of Philadelphia | Phase 1 | 2017-06-27 | The primary study objective is to assess the safety and feasibility of perfluorooctylbromide (PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia (BPD). |
| NCT04738136 ↗ | Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia | Suspended | SolAeroMed Inc. | Phase 2 | 2021-09-15 | This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with moderate severity COVID-19 Bronchiolitis/Pneumonia. |
| NCT04949386 ↗ | Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. | Not yet recruiting | SolAeroMed Inc. | Phase 2 | 2021-09-01 | This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms. Subjects will receive twice daily treatments of either Placebo or S-1226 (8%) for 7 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for perflubron
Condition Name
Clinical Trial Locations for perflubron
Trials by Country
Clinical Trial Progress for perflubron
Clinical Trial Phase
Clinical Trial Sponsors for perflubron
Sponsor Name
